Blue Shield of California’s Wellvolution platform has added four new programs focusing on gut health and weight loss: Ciba Health, Digbi Health, Wondr Health, and an expansion of DarioHealth. Launched in 2019, Wellvolution has helped over 355,000 members lose more than 272,000 pounds through personalized health coaching and digital tools. These new programs offer innovative approaches such as gut microbiome testing and behavioral analysis to tackle chronic diseases like diabetes and obesity. Could these additions be the key to transforming chronic disease management?
Author: Abhay Panchal
This Gastro Bites session is your exclusive opportunity to get insight and ask questions from the authors of the recent AGA Clinical Practice Guideline on Fecal Microbiota-Based Therapies for Select Gastrointestinal Diseases — the first comprehensive guideline on the use of fecal microbiota-based therapies in GI diseases.
A new study from Austria involving 335,466 individuals aged 50+ shows that poor bowel preparation significantly lowers adenoma detection rates and increases the risk of postcolonoscopy colorectal cancer (PCCRC) mortality. Excellent or good bowel prep was achieved in 85% of procedures, but with worsening prep quality, the detection odds for adenomas, high-risk polyps, SSLs, and TSAs decreased sharply. Inadequate prep increased PCCRC death risk by over fourfold. The study emphasizes the importance of high-quality bowel preparation for effective CRC screening.
The AGA Research Scholar Awards are designed to support early-career gastroenterologists and advance the field of gastrointestinal research. These awards provide funding for promising investigators to conduct innovative research, helping to foster the next generation of leaders in gastroenterology. By investing in these scholars, the AGA aims to drive significant scientific advancements and improve patient care.
Eli Lilly is set to acquire Morphic Therapeutic for $3.2 billion in cash, securing Morphic’s lead program, MORF-057, a selective oral small-molecule inhibitor of α4β7 integrin for inflammatory bowel disease (IBD). The deal, expected to close in the third quarter, values Morphic at $57 per share, a 79% premium. MORF-057 has shown promising Phase II results for ulcerative colitis (UC) and is also being tested for Crohn’s disease. This acquisition will expand Lilly’s gastroenterology portfolio, which includes the recently approved UC treatment Omvoh (mirikizumab).
Mainz Biomed has announced its submission for FDA Breakthrough Device Designation for its groundbreaking colorectal cancer (CRC) screening test. This next-generation test combines the Fecal Immunochemical Test (FIT) with advanced mRNA biomarkers and AI technology. Clinical trials demonstrated remarkable accuracy, with a 97% sensitivity for CRC and 88% for advanced adenomas. The non-invasive test offers a highly accurate alternative to traditional methods, potentially revolutionizing CRC diagnostics and reducing mortality rates.
New research indicates that components of the gut microbiome can accurately distinguish children with autism spectrum disorder (ASD) from neurotypical children. By analyzing fecal samples from over 1,600 children, researchers identified specific microorganisms and metabolic pathways altered in ASD. A machine-learning model using these markers achieved a high predictive value for ASD. This study broadens our understanding by including nonbacterial microorganisms, potentially paving the way for noninvasive diagnostic tests and novel therapies. Could this be the key to revolutionizing ASD diagnosis and treatment?
Geneoscopy has filed a countersuit against Exact Sciences, escalating a patent infringement dispute over colorectal cancer screening technologies. The legal battle highlights intense competition in cancer diagnostics and centers on the validity and alleged infringement of Exact Sciences’ patents. Key Issues at Stake: Curious about the details and implications of this legal confrontation? Read the full article.
Heritage Valley Health System has reached a settlement with the Office for Civil Rights (OCR) over HIPAA violations, highlighting critical lessons for healthcare organizations. This case underscores the importance of robust security measures and compliance protocols to protect patient information. What led to this settlement, and what can other healthcare providers learn from this incident?
The EHR-based machine learning model not only outperforms traditional risk scores but also identifies a significantly higher proportion of very-low-risk GIB patients eligible for discharge from emergency departments. This advancement could streamline patient management and improve resource utilization in healthcare settings.Guidelines recommend using risk stratification scores to identify very-low-risk patients with GIB for discharge from emergency departments. Traditional scores like the Glasgow-Blatchford Score (GBS) and Oakland Score require manual data entry and might not utilize all available patient information. This study presents a machine learning model that integrates with the EHR for real-time risk assessment, potentially outperforming existing scores.